Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Corporate Update (June 2024)
18 slides from Zealand Pharma A/s's corporate update, Jun 20, 2024
Slide 1: Petrelintide Topline data 16-week trial (MAD Part 2)
Petrelintide Topline data 16-week trial (MAD Part 2) Zealand Pharma June 20, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda 1 Opening remarks Adam Steensberg, CEO Topline data 2 David Kendall, CMO Phase 1b 16-week trial Agenda 3 Concluding remarks Adam Steensberg, CEO Adam Steensberg, CEO 4 Q&A David Kendall, CMO Henriette Wennicke, CFO 3
Slide 4: Opening remarks
Opening remarks Adam Steensberg, CEO June 20, 2024
Slide 5: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Dapiglutide (GLP-1R/GLP-2R dual agonist) Obesity Obesity Petrelintide (amylin analog) Obesity Obesity ZP6590 (GIP receptor agonist) Obesity
Slide 6: Addressing the greatest healthcare challenge of our time
Addressing the greatest healthcare challenge of our time
Slide 7: GLP-1RA-based therapies are effective at reducing weight but associated with GI tolerability issues
GLP-1RA-based therapies are effective at reducing weight in PwO, but associated with GI tolerability issues1 There is a significant unmet need for alternative treatment options with different mechanisms of action Rx Today, two QW GLP-1RA-based Petrelintide represents an alternative therapies are app
Slide 8: Topline data Phase 1b 16-week trial
Topline data Phase 1b 16-week trial David Kendall, CMO June 20, 2024
Slide 9: Petrelintide is a potential best-in-class amylin analog in development as an alternative to GLP-1RA-based therapy
Petrelintide is a potential best-in-class amylin analog in development as an alternative to GLP-1RA-based therapy Petrelintide (ZP8396) is a 36-amino-acid acylated peptide, based on the peptide sequence of human amylin Long-acting amylin analog (half-life of 10 days), suitable for once-weekly admini
Slide 10: Trial design: Petrelintide Phase 1b MAD Part 2
Trial design: Petrelintide Phase 1b MAD Part 2 A randomized, double-blind, placebo-controlled, Phase 1b, MAD trial of petrelintide – Part 21,2 Aim: to evaluate the safety, tolerability, PK and PD of multiple SC doses of petrelintide, with dose escalation Dosing period Follow-up period Primary endpoi
Slide 11: Baseline characteristics were balanced across the dose cohorts
Baseline characteristics were balanced across the dose cohorts Gender 79% of participants were male Age Median 49 years Weight Median 92.4 kg BMI Median 29.2 kg/m2 Source: Data on file. BMI=body mass index; 11
Slide 12: Petrelintide Phase 1b results: Substantial weight loss observed at 16 weeks
Petrelintide Phase 1b results: Substantial weight loss observed at 16 weeks Change in body weight from baseline at week 16 • Petrelintide treatment resulted in a Petrelintide Petrelintide Petrelintide mean weight loss of up to 8.6% Placebo QW DG 1 QW DG 2 QW DG 3 QW from baseline after 16 weeks N=12
Slide 13: Petrelintide treatment was safe and well-tolerated at all dose levels in the 16-week trial
Petrelintide treatment was safe and well- tolerated at all dose levels in the 16-week trial Proportion of subjects reporting nausea in the 16-week trial • No serious or severe AEs reported • All GI AEs were mild except for two moderate events (nausea and vomiting) reported by one participant Proport
Slide 14: Continuing development of petrelintide as monotherapy through a comprehensive Phase 2b trial
Continuing development of petrelintide as monotherapy through a comprehensive Phase 2b trial A randomized, double-blind, placebo-controlled, Phase 2b trial with petrelintide to be initiated in H2 2024 Aim: to evaluate change in body weight with multiple doses of petrelintide versus placebo Dose Safe
Slide 15: Concluding remarks
Concluding remarks Adam Steensberg, CEO June 20, 2024
Slide 16: 16-week data position petrelintide as a potential best-in-class amylin analog for GLP-1RA-like weight loss
16-week data position petrelintide as a potential best-in-class amylin analog for GLP-1RA-like weight loss Indirect cross-trial comparison of placebo-adjusted percentage change in body weight from baseline at Week 16* Cagrilintide Semaglutide Tirzepatide Petrelintide 2.4 mg QW† 2.4 mg QW 15.0 mg QW
Slide 17: Petrelintide is a potential best-in-class alternative to GLP-1RA-based therapies: Target Product Profile
Petrelintide is a potential best-in-class alternative to GLP-1RA-based therapies: Target Product Profile of… Weight loss – targeting 15-20% mean reduction in body weight as monotherapy, including high-quality weight loss with potential for preservation of lean mass1-4 MoA – mechanism reduces food in
Slide 18: Q&A
Q&A June 20, 2024